Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$442.9MBeat by $73.3M
EPS-$3.58Miss by $2.55
Revenue estimate$369.6M
EPS estimate-$1.03

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$354.7M
EPS estimate$0.17

Financials

Q4 2025

Income statement

See full
Revenue$442.9M—
Net income-$282.8M-278%

Balance sheet

See full
Cash & equivalents$801.3M-27.4%
Total debt$210.6M+2.3%
Total equity$1.1B-25.3%
Total assets$3.3B-15.5%

Cash flow

See full
CapEx$3.6M-90.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.26B-80.6%
Enterprise value$1.66B-84.5%
P/S1×—

Profitability

See full
Net margin-32.5%—

Returns & leverage

See full
Return on equity-53.5%-73.2pp
Debt / equity0.2×0.0×
Current ratio2.3×-1.9×

Segments

By segment

See full
All Other Segments$442.9M-32.7%

By product

See full
Elevidys$110.4M-71.3%

FAQ

When did Sarepta Therapeutics, Inc. report Q4 2025 earnings?
Sarepta Therapeutics, Inc. (SRPT) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Sarepta Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Sarepta Therapeutics, Inc. reported revenue of $442.9M and eps of $-3.58 for Q4 2025.
Did Sarepta Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $369.6M by $73.3M. EPS missed the consensus estimate of $-1.03 by $2.55.
How did Sarepta Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 32.7% from $658.4M a year earlier.
Where can I find Sarepta Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-071566) and the 10-K periodic report (0001193125-26-084144) directly on SEC EDGAR. The filing index links above go to sec.gov.